Collegium Pharmaceuticals, Inc. received an updated ownership report from Eventide Asset Management and related individuals. As of December 31, 2025, Eventide and its affiliates reported beneficial ownership of 1,876,239 shares of Collegium common stock, representing 5.9% of the outstanding shares.
Eventide holds sole voting and dispositive power over these shares, while Finny Kuruvilla and Robin C. John report shared voting and dispositive power over the same 1,876,239 shares. The position is held through registered funds and separately managed accounts, with no single account owning more than 5% of the company’s stock.
The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Collegium. They also formally disclaim beneficial ownership beyond what is required for reporting under beneficial ownership rules.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)
Collegium Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
19459J104
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
19459J104
1
Names of Reporting Persons
Eventide Asset Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,876,239.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,876,239.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,876,239.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP No.
19459J104
1
Names of Reporting Persons
Finny Kuruvilla, M.D. Ph. D.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,876,239.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,876,239.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,876,239.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP No.
19459J104
1
Names of Reporting Persons
Robin C. John
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,876,239.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,876,239.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,876,239.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Collegium Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
100 Technology Center Drive, Stoughton, MA 02072
Item 2.
(a)
Name of person filing:
(i) Eventide Asset Management, LLC ("Eventide")
(ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla")
(iii) Robin C. John ("John")
(b)
Address or principal business office or, if none, residence:
Eventide, Kuruvilla and John:
One International Place, Suite 4210
Boston, Massachusetts 02110
(c)
Citizenship:
Eventide: Delaware
Kuruvilla: United States
John: United States
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
19459J104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
(i) Eventide: 1,876,239
(ii) Kuruvilla: 1,876,239
(iii) John: 1,876,239
(b)
Percent of class:
(i) Eventide: 5.9%
(ii) Kuruvilla: 5.9%
(iii) John: 5.9%
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
As of December 31, 2025, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 1,876,239 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, and Eventide Small Cap ETF, which are registered investment companies, and Eventide separately managed accounts, (the "Accounts"). No Account held more than 5% of the Issuer's outstanding Common Stock.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Eventide Asset Management, LLC
Signature:
/s/ Peter J. Luiso
Name/Title:
Peter J. Luiso, General Counsel
Date:
02/13/2026
Finny Kuruvilla, M.D. Ph. D.
Signature:
/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:
Finny Kuruvilla, M.D., Ph. D.
Date:
02/13/2026
Robin C. John
Signature:
/s/ Robin C. John
Name/Title:
Robin C. John
Date:
02/13/2026
Exhibit Information
EXHIBIT 1
WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;
NOW, THEREFORE, the parties hereto agree as follows:
Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.
Eventide Asset Management, LLC
Date: February 13, 2026
By: /s/ Peter J. Luiso
Name: Peter J. Luiso
Title General Counsel
Finny Kuruvilla, M.D., Ph. D.
Date: February 13, 2026
By: /s/ Finny Kuruvilla, M.D., Ph. D.
Name: Finny Kuruvilla, M.D., Ph. D.
Robin C. John
Date: February 13, 2026
By: /s/ Robin C. John
Name: Robin C. John
What ownership stake in Collegium Pharmaceuticals (COLL) does Eventide report?
Eventide reports beneficial ownership of 1,876,239 shares of Collegium common stock, equal to 5.9% of the outstanding class. This stake is reported as of December 31, 2025, making Eventide and related individuals significant but non-controlling shareholders.
Who are the reporting persons in this Collegium Pharmaceuticals (COLL) Schedule 13G/A?
The reporting persons are Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John. Eventide is organized in Delaware, while Kuruvilla and John are U.S. citizens, jointly reporting their beneficial ownership in Collegium common stock.
How is voting and dispositive power over Collegium (COLL) shares allocated among the filers?
Eventide reports sole voting and dispositive power over 1,876,239 shares. Finny Kuruvilla and Robin C. John each report shared voting and dispositive power over the same 1,876,239 shares, reflecting their roles in connection with Eventide-managed investment accounts.
Are any single Eventide accounts over 5% of Collegium Pharmaceuticals (COLL)?
No individual account exceeds the 5% threshold. The filing states that Eventide manages several funds and separately managed accounts holding Collegium shares and that no single Account held more than 5% of Collegium’s outstanding common stock as of December 31, 2025.
Why do Eventide and the individuals say they hold Collegium (COLL) shares?
They state the Collegium shares were acquired and are held in the ordinary course of business. The filing specifies they were not acquired to change or influence control of Collegium and are not part of any control-related transaction, aside from limited nomination-related activities.
Do the filers claim full beneficial ownership of their Collegium (COLL) position?
The reporting persons expressly disclaim beneficial ownership of the securities beyond what must be reported under applicable rules. They clarify that signing the statement should not be construed as an admission that they are beneficial owners of all reported shares.
